Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of China, Zhengzhou, Henan 450046, China.
Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China.
Biomed Res Int. 2020 Jan 17;2020:5040521. doi: 10.1155/2020/5040521. eCollection 2020.
The role of telemonitoring interventions (TIs) for chronic obstructive pulmonary disease (COPD) has been studied in many systematic reviews (SRs) and meta-analyses (MAs), but robust conclusions have not been reached due to wide variations in scopes, qualities, and outcomes. The aim of this overview was to determine the effectiveness of TIs on COPD patients.
PubMed, EMBASE, Web of Science, and Cochrane Library were searched for all reviews on the topic of TI in treating COPD from inception to July 8, 2019, without restrictions on language. According to the inclusion and exclusion criteria, the retrieved literature studies were screened to select SRs and MAs of randomized control trials (RCTs) that evaluated the effects of TIs in COPD patients. The methodological quality of SRs and MAs was assessed with the AMSTAR-2 tool, and the strength of evidence was assessed with the grades of recommendations, assessment, development, and evaluation (GRADE) system for concerned outcomes in terms of mortality, quality of life (SGRQ total scores), exercise capacity (6MWD), and exacerbation-related outcomes (hospitalizations, exacerbation rate, and emergency room visits).
Our overview included eight SRs and MAs published in 2011 to 2019, from 95 RCTs involving 10632 participants. After strict evaluation by the AMSTAR-2 tool, 75% of the SRs and MAs in this overview had either low or critically low methodological quality. The effects of TIs for COPD on mortality, quality of life, exercise capacity, and exacerbation-related outcomes are limited, and all of these outcomes scored either low or very low quality of evidence on the GRADE system.
There might be insufficient evidence to support the effectiveness of TIs for COPD currently, but the results of this overview should be interpreted dialectically and prudently, and the role of TIs in COPD needs further exploration.
在许多系统评价(SRs)和荟萃分析(MAs)中研究了远程监测干预(TIs)对慢性阻塞性肺疾病(COPD)的作用,但由于范围、质量和结果的广泛差异,尚未得出可靠的结论。本综述的目的是确定 TIs 对 COPD 患者的有效性。
从建库到 2019 年 7 月 8 日,我们在 PubMed、EMBASE、Web of Science 和 Cochrane Library 中搜索了关于 TIs 治疗 COPD 的所有综述,不限制语言。根据纳入和排除标准,筛选检索到的文献研究,选择评价 TIs 对 COPD 患者影响的 SRs 和 MA 的随机对照试验(RCTs)。使用 AMSTAR-2 工具评估 SRs 和 MA 的方法学质量,并使用死亡率、生活质量(SGRQ 总分)、运动能力(6MWD)和与加重相关的结局(住院、加重率和急诊就诊)的推荐、评估、制定和评价(GRADE)系统评估相关结局的证据强度。
我们的综述包括 2011 年至 2019 年发表的 8 篇 SRs 和 MA,涉及 95 项 RCTs,共 10632 名参与者。经过 AMSTAR-2 工具的严格评估,本综述中 75%的 SRs 和 MA 的方法学质量要么较低,要么极低。TIs 对 COPD 的死亡率、生活质量、运动能力和与加重相关的结局的影响有限,在 GRADE 系统中,所有这些结局的证据质量均为低或极低。
目前可能没有足够的证据支持 TIs 对 COPD 的有效性,但本综述的结果应辩证谨慎地解释,TIs 在 COPD 中的作用需要进一步探索。